PMID- 30910989
OWN - NLM
STAT- MEDLINE
DCOM- 20200129
LR  - 20200129
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 78
IP  - 6
DP  - 2019 Jun
TI  - Serum-based soluble markers differentiate psoriatic arthritis from 
      osteoarthritis.
PG  - 796-801
LID - 10.1136/annrheumdis-2018-214737 [doi]
AB  - OBJECTIVES: We aimed to identify soluble biomarkers that differentiate psoriatic 
      arthritis (PsA) from osteoarthritis (OA). METHODS: Markers of cartilage 
      metabolism (cartilage oligomeric matrix protein [COMP], hyaluronan), metabolic 
      syndrome (adiponectin, adipsin, resistin, hepatocyte growth factor [HGF], 
      insulin, leptin) and inflammation (C-reactive protein [CRP], interleukin-1beta 
      [IL-1beta], IL-6, IL-8, tumour necrosis factor alpha [TNFalpha], monocyte 
      chemoattractant protein-1 [MCP-1], nerve growth factor [NGF]) were compared in 
      serum samples from 201 patients with OA, 77 patients with PsA and 76 controls. 
      Levels across the groups were compared using the Kruskal-Wallis test. Pairwise 
      comparisons were made with Wilcoxon rank-sum test. Multivariate logistic 
      regression analyses were performed to identify markers that differentiate PsA 
      from OA. Receiver operating characteristic (ROC) curves were constructed based on 
      multivariate models. The final model was further validated in an independent set 
      of 73 PsA and 75 OA samples using predicted probabilities calculated with 
      coefficients of age, sex and biomarkers. RESULTS: Levels of the following markers 
      were significantly different across the three groups (p<0.001)-COMP, hyaluronan, 
      resistin, HGF, insulin, leptin, CRP, IL-6, IL-8, TNFalpha, MCP-1, NGF. In 
      multivariate analysis, COMP (OR 1.24, 95% CI 1.06 to 1.46), resistin (OR 1.26, 
      95% CI 1.07 to 1.48), MCP-1 (OR 1.10, 95% CI 0.07 to 1.48) and NGF (OR<0.001, 
      95% CI <0.001 to 0.25) were found to be independently associated with PsA versus 
      OA. The area under the ROC curve (AUROC) for this model was 0.99 compared with 
      model with only age and sex (AUROC 0.87, p<0.001). Similar results were obtained 
      using the validation sample. CONCLUSION: A panel of four biomarkers may 
      distinguish PsA from OA. These results need further validation in prospective 
      studies.
CI  - (c) Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Chandran, Vinod
AU  - Chandran V
AUID- ORCID: 0000-0002-8297-0275
AD  - Division of Rheumatology, Department of Medicine, University of Toronto, Toronto 
      Western Hospital, Toronto, Ontario, Canada.
FAU - Abji, Fatima
AU  - Abji F
AD  - Rheumatology Research, University of Toronto, University Health Network, Toronto, 
      Ontario, Canada.
FAU - Perruccio, Anthony V
AU  - Perruccio AV
AD  - Arthritis Program, University Health Network, Toronto, Ontario, Canada.
AD  - Surgery, University of Toronto, Toronto, Ontario, Canada.
FAU - Gandhi, Rajiv
AU  - Gandhi R
AD  - Division of Orthopaedic Surgery, Department of Surgery, Toronto Western Hospital, 
      Toronto, Ontario, Canada.
FAU - Li, Suzanne
AU  - Li S
AD  - Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 
      University Health Network, Toronto, Ontario, Canada.
FAU - Cook, Richard J
AU  - Cook RJ
AD  - Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, 
      Canada.
FAU - Gladman, Dafna D
AU  - Gladman DD
AUID- ORCID: 0000-0002-9074-0592
AD  - Division of Rheumatology, Department of Medicine, University of Toronto, Toronto 
      Western Hospital, Toronto, Ontario, Canada dafna.gladman@utoronto.ca.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190325
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (COMP protein, human)
RN  - 0 (Cartilage Oligomeric Matrix Protein)
RN  - 0 (Chemokine CCL2)
RN  - 0 (NGF protein, human)
RN  - 0 (RETN protein, human)
RN  - 0 (Resistin)
RN  - 9061-61-4 (Nerve Growth Factor)
SB  - IM
CIN - Ann Rheum Dis. 2020 Sep;79(9):e112. PMID: 31154321
CIN - Ann Rheum Dis. 2020 Sep;79(9):e113. PMID: 31272941
MH  - Adult
MH  - Aged
MH  - Arthritis, Psoriatic/*diagnosis
MH  - Biomarkers/blood
MH  - Cartilage Oligomeric Matrix Protein/blood
MH  - Chemokine CCL2/blood
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nerve Growth Factor/blood
MH  - Osteoarthritis/*diagnosis
MH  - ROC Curve
MH  - Reproducibility of Results
MH  - Resistin/blood
MH  - Severity of Illness Index
MH  - Solubility
OTO - NOTNLM
OT  - biomarkers
OT  - osteoarthritis
OT  - psoriatic arthritis
COIS- Competing interests: None declared.
EDAT- 2019/03/27 06:00
MHDA- 2020/01/30 06:00
CRDT- 2019/03/27 06:00
PHST- 2018/11/09 00:00 [received]
PHST- 2019/02/24 00:00 [revised]
PHST- 2019/02/26 00:00 [accepted]
PHST- 2019/03/27 06:00 [pubmed]
PHST- 2020/01/30 06:00 [medline]
PHST- 2019/03/27 06:00 [entrez]
AID - annrheumdis-2018-214737 [pii]
AID - 10.1136/annrheumdis-2018-214737 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2019 Jun;78(6):796-801. doi: 10.1136/annrheumdis-2018-214737. Epub 
      2019 Mar 25.